Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia
Bichoy Gabra, Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center, shared on X:
“Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager (BiTE) molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, has significantly improved overall survival in MDR-negative BCP-ALL.”
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Authors: Mark R. Litzow, Zhuoxin Sun, Ryan J. Mattison, Elisabeth M. Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevskis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W. Pratz, Shira N. Dinner, Noelle Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Cheryl L. Willman, Daniel J. DeAngelo, Shejal B. Patel, Michelle A. Elliott, Anjali S. Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali R. Bhave, Elad Sharon, Richard F. Little, Harry P. Erba, Richard M. Stone, Selina M. Luger, Charles G. Mullighan and Martin S. Tallman.
List of Approved BiTE Antibodies in Hematology/Oncology.
Source: Bichoy Gabra/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023